Progenics Form 8-K officer comp 2 20 06
 
 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported) February 20, 2006
 
 
Progenics Pharmaceuticals, Inc.
 
 
 
 
 
(Exact name of registrant as specified in its charter)
 

 
Delaware
 
000-23143
 
13-3379479
 
 
  
 
  
 
  
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

 
 
777 Old Saw Mill River Road, Tarrytown, New York
10591
 
 
 
 
(Address of principal executive offices)
(Zip Code)
 
Registrant's telephone number, including area code (914) 789-2800                   
 
 
 
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
           o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
           o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
          o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
           o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 Section 1 - Registrant’s Business and Operations
 
 
Item 1.01 Entry into a Material Definitive Agreement.
 
 
At its meeting on February 20, 2006, the Compensation Committee of the Board of Directors of Progenics Pharmaceuticals, Inc. approved the following salary increases for 2006 and made the following cash bonus awards for 2005 to the specified named executive officers (as defined in Regulation S-K Item 402(a)(3)) of the Company:
 
Name
 
 
Title
 
 
2005 Salary
    
2006 Salary
    
Cash Bonus
 
Mark R. Baker
 
 
Senior Vice President and
General Counsel
 
$
280,000
 
$
300,000
 
$
200,000
 
Robert J. Israel, M.D.
 
 
Senior Vice President, Medical Affairs
 
 
312,000
 
 
325,000
 
 
125,000
 
Alton B. Kremer, M.D.
 
 
Vice President, Clinical Research
 
 
320,000
 
 
340,000
 
 
125,000
 
Robert A. McKinney
 
 
Senior Vice President,
Finance and Operations
Chief Financial Officer
 
 
230,000
 
 
250,000
 
 
150,000
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
                    PROGENICS PHARMACEUTICALS, INC.

                    By:  /s/ Robert A. McKinney      
                        Robert A. McKinney
                        Senior Vice President, Finance and Operations
                        Chief Financial Officer
 
 
Date: February 22, 2006